Evidence map›Paper›PMID 26908565›Full record

Trial reportCancer prevention research (Philadelphia, Pa.)2016

The Effect of Atorvastatin on Breast Cancer Biomarkers in High-Risk Women.

YongLi Ji, Tiffany Rounds, Abigail Crocker, Betsy Sussman, Russell C Hovey, Fonda Kingsley, Hyman B Muss, Judy E Garber, Marie E Wood

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer prevention research (Philadelphia, Pa.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Medication use and mammographic breast density.Breast cancer research and treatment · 2021
    Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. The dichotomous role of HBiochemical pharmacology · 2018
    Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

YongLi JiDepartment of Medicine, University of Vermont, Burlington, Vermont.
Tiffany RoundsDepartment of Medicine, University of Vermont, Burlington, Vermont.
Abigail CrockerDepartment of Mathematics and Statistics, University of Vermont, Burlington, Vermont.
Betsy SussmanDepartment of Radiology, University of Vermont, Burlington, Vermont.
Russell C HoveyUniversity of California, Davis, California.
Fonda KingsleyDepartment of Medicine, University of Vermont, Burlington, Vermont.
Hyman B MussUniversity of North Carolina, Chapel Hill, North Carolina.
Judy E GarberDana-Farber Cancer Institute, Boston, Massachusetts.
Marie E WoodDepartment of Medicine, University of Vermont, Burlington, Vermont. Marie.Wood@uvm.edu.
Dana-Farber Cancer Institute · USUniversity of North Carolina at Chapel Hill · US

Funding

Alliance NCORP Research BaseUG1CA189823 · ALLIANCE NCTN FOUNDATION · 2025 to 2025
$7.9M
RESEARCH BASE SUPPORT FOR COMMUNITY CLINICAL ONCOLOGY PRU10CA037447 · UNIVERSITY OF CHICAGO · 1985 to 2005
$7.8M
NCI NIH HHS U10 CA037447NCI NIH HHS U10 CA180867NCI NIH HHS UG1 CA189823
6 · The paper itself

Abstract

Statins have the potential to reduce breast cancer incidence and recurrence as shown in both epidemiologic and laboratory studies. The purpose of this study was to evaluate the effect of a lipophilic statin, atorvastatin, on breast cancer biomarkers of risk [mammographic density (MD) and insulin growth factor 1 (IGF-1)] in high-risk premenopausal women.Premenopausal women at increased risk for breast cancer received either 40 mg of atorvastatin or placebo for 1 year. Biomarker assessment was performed prior to initiation and at completion of study medication. MD was determined using both Breast Imaging Reporting and Data System and the visual analogue scale. Serum IGF-1 was determined by ELISA assay at the end of the study.Sixty-three women were enrolled between December 2005 and May 2010. Sixteen (25%) women withdrew. The mean age of participants was 43 (range, 35-50), 100% were white, and the average body mass index (BMI) was 26.4. The statin group demonstrated a significant decrease in cholesterol and low-density lipoprotein (LDL), suggesting compliance with study medication. After accounting for BMI, there was no difference in change in MD between groups. There was a significant increase in serum IGF-1 in the statin group.In this multi-institutional randomized prospective clinical trial of premenopausal women at increased risk for breast cancer, we did not see an effect of atorvastatin on MD. Further investigation of statins may be warranted; however, design of prior trials and potential mechanism of action of the agent need to be considered in the design of future trials. Cancer Prev Res; 9(5); 379-84. ©2016 AACR.

Indexed as

AdultAtorvastatinBiomarkers, TumorBreast NeoplasmsFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMiddle AgedPremenopauseRisk FactorsAtorvastatinBiomarkers, TumorHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID26908565
PMCPMC4965880
OpenAlexW2281717253

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.